Polyendocrine metabolic ovarian syndrome (PMOS), previously termed polycystic ovary syndrome (PCOS), is a prevalent endocrine disorder in women of reproductive age characterized by reproductive, metabolic, and psychological sequelae. The authors framed the study to address the need for safe, effective treatments that improve both clinical symptoms and fertility-related outcomes. The report compares a combination herbal/formulation therapy, VAMHA and MYRHA, with a standard non-hormonal regimen of Metformin plus Myoinositol for comprehensive PMOS management.
This was an open-label, randomized, multicentre, prospective comparative clinical study. Seventy-one women with PMOS were randomized into two groups: Group A (n=37) and Group B (n=34). The trial was conducted across multiple clinical centres in India; Institutional Ethics Committee approvals were obtained at the participating sites. The trial was registered with CTRI (CTRI/2022/12/048147). The authors report that all participants provided informed consent and that necessary ethical oversight and approvals were in place.
Group A received a combination regimen of VAMHA and MYRHA tablets, two tablets each, administered twice daily for 180 days. Group B received Metformin 500 mg plus Myoinositol 600 mg (one tablet), administered twice daily for 180 days. Data were recorded in case report forms throughout the treatment period.
The primary objective was restoration of regular menstruation. Secondary objectives included assessment of ovulation, menstrual symptoms, polycystic ovarian morphology on ultrasound, hormonal and metabolic parameters (including Anti-Mullerian Hormone and fasting insulin), anthropometric measures (including BMI), and skin manifestations. Continuous variables were summarized with mean and standard deviation; categorical variables were reported as frequencies and percentages. Statistical tests appropriate to the data, including Chi-square where applicable, were applied. A p-value ≤0.05 was considered statistically significant.
The study reports that a significantly greater number of participants in the VAMHA and MYRHA group (Group A) achieved regular menstrual cycles compared with the Metformin–Myoinositol group (Group B). Specifically, 31 participants in Group A achieved regular cycles versus 22 in Group B, a difference reported as statistically significant (p<0.05). Both treatment arms, however, showed significant improvement from baseline in measures of menstrual irregularity and related symptoms.
Ovulation occurrence during the study period favored the VAMHA–MYRHA combination: 16 participants in Group A ovulated compared with 6 in Group B (p<0.05). Regarding ultrasound findings, resolution of polycystic ovarian morphology was reported in 13 participants (38.23%) in Group A and 10 participants (33.33%) in Group B. The manuscript presents these sonographic outcomes as part of the comprehensive response to therapy.
Both groups demonstrated statistically significant reductions in Anti-Mullerian Hormone (AMH) and fasting insulin levels, as well as reductions in BMI (p<0.05). The authors report these hormonal and metabolic changes alongside improvements in clinical symptoms, indicating metabolic and endocrine benefits across both treatment strategies.
The report states that both the VAMHA–MYRHA combination and the Metformin–Myoinositol regimen were well tolerated. No major safety concerns were documented in the manuscript. The authors declare no competing interests.
The trial is registered (CTRI/2022/12/048147) and received IEC approvals at the participating centres with dates provided in the manuscript. The authors confirm participant consent and adherence to ethical guidelines. They state that all data produced in the work are contained within the manuscript.
In this randomized, open-label multicentre study of 71 women with PMOS treated for 180 days, the combination of VAMHA and MYRHA produced superior outcomes in restoring menstrual regularity and in rates of ovulation compared with a standard non-hormonal regimen of Metformin plus Myoinositol. Both treatments improved menstrual symptoms, led to reductions in AMH, fasting insulin, and BMI, and had favourable effects on polycystic ovarian morphology, with good tolerability reported. As this report is a medRxiv preprint and has not undergone peer review, the authors and publishers note that these findings should not yet be used to guide clinical practice until further validation.